PACIRA BIOSCIENCES, INC. Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross
PACIRA BIOSCIENCES, INC. (PCRX) reported Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross of 300.60 thousand shares for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-04.
Financial Statements › Shareholders' Equity › Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Net of Forfeitures
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross · last filed 2026-08-04
- PACIRA BIOSCIENCES, INC. share-based compensation arrangement by share-based payment award, options, grants in period, gross for the quarter ending 2026-06-30 was 186.91K shares, a 3.65% increase year-over-year.
- PACIRA BIOSCIENCES, INC. share-based compensation arrangement by share-based payment award, options, grants in period, gross for the quarter ending 2026-03-31 was 113.69K shares, a 54.94% decline year-over-year.
- PACIRA BIOSCIENCES, INC. share-based compensation arrangement by share-based payment award, options, grants in period, gross for the quarter ending 2025-12-31 was 52.55K shares, a 82.93% decline year-over-year.
- PACIRA BIOSCIENCES, INC. share-based compensation arrangement by share-based payment award, options, grants in period, gross for the quarter ending 2025-09-30 was 52.60K shares, a 19.20% decline year-over-year.
- PACIRA BIOSCIENCES, INC. share-based compensation arrangement by share-based payment award, options, grants in period, gross for fiscal 2025 was 537.79K shares, a 63.47% decline from fiscal 2024.
- PACIRA BIOSCIENCES, INC. share-based compensation arrangement by share-based payment award, options, grants in period, gross for fiscal 2024 was 1.47M shares, a 7.26% decline from fiscal 2023.
- PACIRA BIOSCIENCES, INC. share-based compensation arrangement by share-based payment award, options, grants in period, gross for fiscal 2023 was 1.59M shares, a 49.53% increase from fiscal 2022.
- PACIRA BIOSCIENCES, INC. share-based compensation arrangement by share-based payment award, options, grants in period, gross for fiscal 2022 was 1.06M shares, a 19.25% increase from fiscal 2021.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross 12 month |
|---|---|---|---|---|
| 2026-06-30 | 186.91K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-04 | 300.60K shares 10-Q · filed 2026-08-04 | 353.16K shares derived: sum of 3 quarters · filed 2026-08-04 | 405.76K shares derived: sum of 4 quarters · filed 2026-08-04 |
| 2026-03-31 | 113.69K shares 10-Q · filed 2026-04-30 | 166.25K shares derived: sum of 2 quarters · filed 2026-04-30 | 218.85K shares derived: sum of 3 quarters · filed 2026-04-30 | 399.18K shares derived: sum of 4 quarters · filed 2026-04-30 |
| 2025-12-31 | 52.55K shares derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | 105.16K shares derived: sum of 2 quarters · filed 2026-02-26 | 285.49K shares derived: sum of 3 quarters · filed 2026-02-26 | 537.79K shares 10-K · filed 2026-02-26 |
| 2025-09-30 | 52.60K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | 232.93K shares derived: sum of 2 quarters · filed 2025-11-06 | 485.23K shares 10-Q · filed 2025-11-06 | 793.13K shares derived: sum of 4 quarters · filed 2025-11-06 |
| 2025-06-30 | 180.33K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-05 | 432.63K shares 10-Q · filed 2025-08-05 | 740.53K shares derived: sum of 3 quarters · filed 2025-08-05 | 805.63K shares derived: sum of 4 quarters · filed 2025-08-05 |
| 2025-03-31 | 252.30K shares 10-Q · filed 2025-05-08 | 560.20K shares derived: sum of 2 quarters · filed 2025-05-08 | 625.30K shares derived: sum of 3 quarters · filed 2025-05-08 | 823.53K shares derived: sum of 4 quarters · filed 2025-05-08 |
| 2024-12-31 | 307.90K shares derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-27 | 373.00K shares derived: sum of 2 quarters · filed 2025-02-27 | 571.23K shares derived: sum of 3 quarters · filed 2025-02-27 | 1.47M shares 10-K · filed 2025-02-27 |
| 2024-09-30 | 65.10K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-06 | 263.33K shares derived: sum of 2 quarters · filed 2024-11-06 | 1.16M shares 10-Q · filed 2024-11-06 | 1.32M shares derived: sum of 4 quarters · filed 2024-11-06 |
| 2024-06-30 | 198.23K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2024-07-30 | 1.10M shares 10-Q · filed 2024-07-30 | 1.25M shares derived: sum of 3 quarters · filed 2024-07-30 | 1.26M shares derived: sum of 4 quarters · filed 2024-07-30 |
| 2024-03-31 | 901.00K shares 10-Q · filed 2024-05-07 | 1.05M shares derived: sum of 2 quarters · filed 2024-05-07 | 1.06M shares derived: sum of 3 quarters · filed 2024-05-07 | 2.35M shares derived: sum of 4 quarters · filed 2024-05-07 |
| 2023-12-31 | 152.27K shares derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-29 | 161.07K shares derived: sum of 2 quarters · filed 2024-02-29 | 1.45M shares derived: sum of 3 quarters · filed 2024-02-29 | 1.59M shares 10-K · filed 2024-02-29 |
| 2023-09-30 | 8.80K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-02 | 1.29M shares derived: sum of 2 quarters · filed 2023-11-02 | 1.44M shares 10-Q · filed 2023-11-02 | 1.46M shares derived: sum of 4 quarters · filed 2024-02-29 |
| 2023-06-30 | 1.29M shares derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-02 | 1.43M shares 10-Q · filed 2023-08-02 | 1.45M shares derived: sum of 3 quarters · filed 2024-02-29 | 1.48M shares derived: sum of 4 quarters · filed 2024-02-29 |
| 2023-03-31 | 141.20K shares 10-Q · filed 2023-05-03 | 168.60K shares derived: sum of 2 quarters · filed 2024-02-29 | 192.05K shares derived: sum of 3 quarters · filed 2024-02-29 | 1.08M shares derived: sum of 4 quarters · filed 2024-02-29 |
| 2022-12-31 | 27.40K shares derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-29 | 50.85K shares derived: sum of 2 quarters · filed 2024-02-29 | 941.43K shares derived: sum of 3 quarters · filed 2024-02-29 | 1.06M shares 10-K · filed 2024-02-29 |
| 2022-09-30 | 23.45K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-03 | 914.03K shares derived: sum of 2 quarters · filed 2022-11-03 | 1.03M shares 10-Q · filed 2022-11-03 | 1.16M shares derived: sum of 4 quarters · filed 2024-02-29 |
| 2022-06-30 | 890.58K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-03 | 1.01M shares 10-Q · filed 2022-08-03 | 1.13M shares derived: sum of 3 quarters · filed 2024-02-29 | 1.21M shares derived: sum of 4 quarters · filed 2024-02-29 |
| 2022-03-31 | 120.20K shares 10-Q · filed 2022-05-04 | 241.13K shares derived: sum of 2 quarters · filed 2024-02-29 | 318.13K shares derived: sum of 3 quarters · filed 2024-02-29 | 966.98K shares derived: sum of 4 quarters · filed 2024-02-29 |
| 2021-12-31 | 120.92K shares derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-29 | 197.93K shares derived: sum of 2 quarters · filed 2024-02-29 | 846.78K shares derived: sum of 3 quarters · filed 2024-02-29 | 890.28K shares 10-K · filed 2024-02-29 |
| 2021-09-30 | 77.00K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-03 | 725.85K shares derived: sum of 2 quarters · filed 2021-11-03 | 769.35K shares 10-Q · filed 2021-11-03 | 802.15K shares derived: sum of 4 quarters · filed 2023-02-28 |
| 2021-06-30 | 648.85K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-03 | 692.35K shares 10-Q · filed 2021-08-03 | 725.15K shares derived: sum of 3 quarters · filed 2023-02-28 | 848.45K shares derived: sum of 4 quarters · filed 2023-02-28 |
| 2021-03-31 | 43.50K shares 10-Q · filed 2021-05-04 | 76.30K shares derived: sum of 2 quarters · filed 2023-02-28 | 199.60K shares derived: sum of 3 quarters · filed 2023-02-28 | |
| 2020-12-31 | 32.80K shares derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-28 | 156.10K shares derived: sum of 2 quarters · filed 2023-02-28 | 1.50M shares 10-K · filed 2023-02-28 | |
| 2020-09-30 | 123.30K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2020-10-30 | 1.47M shares 10-Q · filed 2020-10-30 | ||
| 2020-06-30 | 1.35M shares 10-Q · filed 2020-08-06 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Janux Therapeutics, Inc. (JANX) | United States | $1.019B | -9.15 |
| MoonLake Immunotherapeutics (MLTX) | Switzerland | $1.031B | -5.43 |
| Savara Inc (SVRA) | United States | $1.044B | -9.10 |
| Corvus Pharmaceuticals, Inc. (CRVS) | United States | $0.994B | -23.25 |
| MANNKIND CORP (MNKD) | United States | $1.058B | -30.41 |
| Alto Neuroscience, Inc. (ANRO) | United States | $1.065B | -11.02 |
| Kura Oncology, Inc. (KURA) | United States | $0.967B | -3.29 |
| Arbutus Biopharma Corp (ABUS) | $0.965B | 6.19 | |
| Jade Biosciences, Inc. (JBIO) | United States | $0.936B | -9.21 |
| Amphastar Pharmaceuticals, Inc. (AMPH) | United States | $1.116B | 10.93 |